Production (Stage)
Genomma Lab Internacional, S.A.B. de C.V.
GNMLF
$1.09
-$0.15-12.10%
OTC PK
| 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 8.95% | 8.95% | 10.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 8.95% | 8.95% | 10.26% |
| Cost of Revenue | -- | -- | 1.36% | 1.36% | 4.41% |
| Gross Profit | -- | -- | 13.95% | 13.95% | 14.13% |
| SG&A Expenses | -- | -- | 12.47% | 12.47% | 14.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 290.52% | 290.52% | 338.84% |
| Total Operating Expenses | -- | -- | 7.99% | 7.99% | 9.54% |
| Operating Income | -- | -- | 12.97% | 12.97% | 13.25% |
| Income Before Tax | -- | -- | 1.27% | 4.31% | -8.34% |
| Income Tax Expenses | -- | -- | -0.87% | -0.87% | -12.25% |
| Earnings from Continuing Operations | -- | -- | 2.43% | 7.15% | -6.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 2.43% | 2.43% | -10.95% |
| EBIT | -- | -- | 12.97% | 12.97% | 13.25% |
| EBITDA | -- | -- | 12.92% | 12.92% | 13.56% |
| EPS Basic | -- | -- | 6.01% | 6.80% | -7.70% |
| Normalized Basic EPS | -- | -- | 5.42% | 9.21% | -4.43% |
| EPS Diluted | -- | -- | 6.01% | 6.80% | -7.70% |
| Normalized Diluted EPS | -- | -- | 5.42% | 9.21% | -4.43% |
| Average Basic Shares Outstanding | -- | -- | -3.56% | -4.16% | -3.86% |
| Average Diluted Shares Outstanding | -- | -- | -3.56% | -4.16% | -3.86% |
| Dividend Per Share | -- | -- | -15.85% | -15.85% | 52.51% |
| Payout Ratio | -- | -- | 0.46% | 0.46% | 0.28% |